India to expand domestic vaccine options
Surge of cases drives decision on COVID shots authorized by the WHO and others.
NEW DELHI — India said Tuesday that it would approve the use of all COVID-19 vaccines that had been given an emergency nod by the World Health Organization or regulators in the United States, Europe, Britain or Japan.
India’s Health Ministry said the decision was aimed at hastening the use of shots made in other countries and expanding the “basket of vaccines” available for domestic use. The country of almost 1.4 billion people is seeing a crippling surge of infections that is threatening to overwhelm hospitals in hard-hit cities.
The only way out of the crisis, experts say, is to vaccinate more people.
But this has global implications since India is a major vaccine producer and its domestic needs have delayed the delivery of shots to the U.N.-backed COVAX initiative that is aimed at distributing vaccines equitably.
India had earlier given the nod to the AstraZeneca vaccine made by Serum Institute of India and another one made by the Indian company Bharat Biotech.
Now, vaccines that have received emergency-use authorization by regulators in the U.S., Europe, Britain, Japan or the World Health Organization can be used in India. The Health Ministry also said Tuesday that the Russian Sputnik V vaccine had been greenlighted for emergency use.
The Health Ministry said safety would be monitored in the first 100 people who received these shots before their use was expanded to include others.
Dr. Shahid Jameel, who studies viruses at India’s Ashoka University, said that although the move was unlikely to help the country deal with the surge it was currently experiencing, it would help in vaccine availability going forward, consequently freeing up vaccines that could then be exported.
He said this would pave the path for India to use vaccines made by companies with a manufacturing partner in India. For instance, vaccine maker Biological E Ltd. is contracted to make the Johnson & Johnson COVID-19 vaccine.
Jameel added that this would potentially open up the market for vaccines that required ultra-cold storage facilities to be sold in cities where such facilities were available.
Vaccine prices in India are currently capped at 250 rupees, or $3.30. This will also free up the government to subsidize the vaccines for the poor, while those who can afford to buy more expensive vaccines can do so.
Russia has agreements with five Indian pharmaceutical companies to make more than 850 million doses of Sputnik V vaccine in India for the world. It has also signed a deal with Dr. Reddy’s Laboratories to conduct late trials and distribute up to 250 million doses in India.
But with four of Russia’s five deals signed in March and April, the doses are likely to be supplied later in the year. Moreover, Russia’s first manufacturing deal with India was with Hetero Biopharma for 100 million doses — but it is unclear whether it has started making doses. Hetero Biopharma didn’t respond to queries from AP.